Thoracoscopy-Guided Diagnosis and Therapy in Early-Stage Lung Cancer

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 5669

Special Issue Editors


E-Mail
Guest Editor
Department of Surgery, National Taiwan University Cancer Center, National Taiwan University College of Medicine, Taipei 106037, Taiwan
Interests: lung cancer; minimally invasive surgery; non-intubated thoracoscopic surgery; thoracic malignancy

E-Mail
Guest Editor
Department of Surgery, National Taiwan University Cancer Center, National Taiwan University College of Medicine, Taipei 106037, Taiwan
Interests: lung transplantation; pulmonary hypertension; lung cancer; minimally invasive surgery

E-Mail Website
Guest Editor
Department of Surgery, National Taiwan University Cancer Center, National Taiwan University College of Medicine, Taipei 106037, Taiwan
Interests: minimally invasive thoracic surgery; thoracic pathological research; thoracic radiomic research
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Thoracoscopy is an increasingly common procedure that provides significant clinical information and therapeutic applications. The procedure allows the physician to biopsy the parietal pleura under direct visualization with high accuracy. Medical thoracoscopy is less invasive, has a comparable diagnostic yield, and may be better tolerated in high-risk patients. In the era of rapidly evolving diagnostics and therapeutics for lung cancer, thoracoscopy will play a pivotal role in evaluation and research. This Special Issue of Diagnostics will mainly focus on the advances of thoracoscopy applications in the diagnosis and therapy of early-stage lung cancer.

Prof. Dr. Jin-Shing Chen
Prof. Dr. Hsao-Hsun Hsu
Dr. Mong-Wei Lin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • thoracoscopy
  • lung cancer
  • intervention

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

8 pages, 37044 KiB  
Article
A Preclinical Feasibility Study of Single-Port Robotic Subcostal Anatomical Lung Resection and Subxiphoid Thymectomy Using the da Vinci® SP System
by Ching Feng Wu, Chuan Cheng, Ka Hei Suen, Hubert Stein and Yin Kai Chao
Diagnostics 2023, 13(3), 460; https://doi.org/10.3390/diagnostics13030460 - 26 Jan 2023
Cited by 8 | Viewed by 1909
Abstract
Despite the recent introduction of technologically advanced single-port (SP) robotic systems, their use in the field of thoracic surgery has been rarely explored. Here, we report our preclinical experience concerning SP robotic thoracic surgery using the da Vinci® SP system. The da [...] Read more.
Despite the recent introduction of technologically advanced single-port (SP) robotic systems, their use in the field of thoracic surgery has been rarely explored. Here, we report our preclinical experience concerning SP robotic thoracic surgery using the da Vinci® SP system. The da Vinci® SP system was used to perform subcostal anatomical lung resection and subxiphoid thymectomy in three cadavers. The operative settings that best met the surgeon’s requirements for each resection were also determined. Four subcostal anatomical lung resections and two subxiphoid thymectomies were completed. While both procedures did not require additional incisions, the use of an observation port in the intercostal spaces was strongly recommended to safely create subcostal access. Dissection of hilar structures and mediastinal lymph nodes was feasible. However, due to the current unavailability of a robotic stapler, a handheld stapling instrument was required to perform a transection of vital structures. When the stapling process proved to be difficult, the table surgeon temporarily removed a robotic arm to acquire the necessary space to complete the procedure. Our data represent a promising preclinical step in understanding the feasibility of using the da Vinci® SP system to perform an SP subcostal anatomical lung resection and a subxiphoid thymectomy. Full article
(This article belongs to the Special Issue Thoracoscopy-Guided Diagnosis and Therapy in Early-Stage Lung Cancer)
Show Figures

Figure 1

12 pages, 1296 KiB  
Article
Clinicopathological Features and Significance of Epidermal Growth Factor Receptor Mutation in Surgically Resected Early-Stage Lung Adenocarcinoma
by Chao-Wen Lu, Mong-Wei Lin, Xu-Heng Chiang, Hsao-Hsun Hsu, Min-Shu Hsieh and Jin-Shing Chen
Diagnostics 2023, 13(3), 390; https://doi.org/10.3390/diagnostics13030390 - 20 Jan 2023
Cited by 1 | Viewed by 1267
Abstract
The clinicopathological presentation of early-stage lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutations has been seldom studied. Our study enrolled patients with stage I and II lung adenocarcinoma between January 2014 and December 2017 at the National Taiwan University Hospital. Clinicopathological [...] Read more.
The clinicopathological presentation of early-stage lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutations has been seldom studied. Our study enrolled patients with stage I and II lung adenocarcinoma between January 2014 and December 2017 at the National Taiwan University Hospital. Clinicopathological features and prognosis were retrospectively reviewed and analyzed depending on EGFR mutation status. EGFR mutations were detected in 622 (60%) out of 1034 patients. Compared to the group without EGFR mutations, the group with EGFR mutations had more patients above 65 years of age (p < 0.001), more non-lepidic histological subtypes (p < 0.001), higher CEA levels (p = 0.044), higher grade of pleural (p = 0.02) and lymphovascular (p = 0.001) invasion, higher histological grade (p < 0.001), and a more advanced pathological stage (p = 0.022). In multivariate analysis, there was no significant difference in PFS or OS between the EGFR mutant and wild-type groups. In subtype analysis, the tumors with an L858R mutation had a more lepidic predominant histological type (p = 0.019) and less lymphovascular invasion (p = 0.011). No significant differences in PFS or OS were detected between the exon 19 deletion and L858R mutation groups. In early-stage lung adenocarcinoma, EGFR mutation may be considered as a treatment response predictor for tyrosine kinase inhibitors, instead of a predictor of clinical prognosis. Full article
(This article belongs to the Special Issue Thoracoscopy-Guided Diagnosis and Therapy in Early-Stage Lung Cancer)
Show Figures

Figure 1

Review

Jump to: Research

18 pages, 21618 KiB  
Review
Uniportal VATS for Diagnosis and Staging in Non-Small Cell Lung Cancer (NSCLC)
by Jone Miren Del Campo, Sergio Maroto, Leyre Sebastian, Xavier Vaillo, Sergio Bolufer, Francisco Lirio, Julio Sesma and Carlos Galvez
Diagnostics 2023, 13(5), 826; https://doi.org/10.3390/diagnostics13050826 - 21 Feb 2023
Cited by 1 | Viewed by 1846
Abstract
Uniportal VATS has become an accepted approach in minimally invasive thoracic surgery since its first report for lobectomy in 2011. Since the initial restrictions in indications, it has been used in almost all procedures, from conventional lobectomies to sublobar resections, bronchial and vascular [...] Read more.
Uniportal VATS has become an accepted approach in minimally invasive thoracic surgery since its first report for lobectomy in 2011. Since the initial restrictions in indications, it has been used in almost all procedures, from conventional lobectomies to sublobar resections, bronchial and vascular sleeve procedures and even tracheal and carinal resections. In addition to its use for treatment, it provides an excellent approach for suspicious solitary undiagnosed nodules after bronchoscopic or transthoracic image-guided biopsy. Uniportal VATS is also used as a surgical staging method in NSCLC due to its low invasiveness in terms of chest tube duration, hospital stay and postoperative pain. In this article, we review the evidence of uniportal VATS accuracy for NSCLC diagnosis and staging and provide technical details and recommendations for its safe performance for that purpose. Full article
(This article belongs to the Special Issue Thoracoscopy-Guided Diagnosis and Therapy in Early-Stage Lung Cancer)
Show Figures

Figure 1

Back to TopTop